Zusammenfassung
Das Prostatakarzinom wird bei älteren Menschen über 75 Jahren gehäuft später und mit höheren Risikofaktoren diagnostiziert. Die Wahrscheinlichkeit des krankheitsspezifischen Versterbens ist höher als in jüngeren Altersgruppen, so dass insbesondere bei geringer Komorbidität eine Unterbehandlung vermieden werden sollte. Die Strahlentherapie ist eine gut verträgliche und in dieser Altersgruppe zunehmend eingesetzte Behandlungsmethode in kurativer palliativer Intention. Hypofraktionierte Strahlentherapieschemata verkürzen die Gesamtbehandlungszeit und können zunehmend evidenzbasiert eingesetzt werden. Mit der bildgeführten hochkonformalen intensitätsmodulierten Radiotherapie (IMRT) wird eine Verträglichkeit der Therapie durch enge Anpassung des Hochdosisbereichs an das Zielvolumen erreicht.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Aas K, Fossa SD, Myklebust TA et al (2020) Increased curative treatment is associated with decreased prostate cancer-specific and overall mortatility in senior adults with high-risk prostate cancer; results from a national registry-based cohort study. Cancer Med 9:6646–6657
Abdollah F, Boorjian S, Cozzarini C et al (2013) Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol 64:557–564
Bechis SK, Carroll PR, Cooperberg MR (2011) Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29:235–241
Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a ranomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027
Charlson M, Szatrowski TP, Peterson J et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251
Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomized, non-inferiority, phase 3 CHHip trial. Lancet Oncol 17:1047–1060
Gomez-Millan J (2009) Radiation therapy in the elderly: more side effects and complications? Crit Rev Oncol Hematol 71:70–78
Hoffman KE (2012) Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidty. Semin Radiat Oncol 22:284–294
Knipper S, Pecoraro A, Palumbo C et al (2020) The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes Control 31:283–290
Kuban DA, Levy LB, Cheung R et al (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. who dies of disease? Int J Radiat Oncol Biol Phys 79:1310–1317
Lawton CA, Bae K, Pilepich M et al (2008) Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation oncology group studies 85–31, 86–10, and 92–02. Int J Radiat Oncol Biol Phys 70:437–441
Lutz S, Berl L, Chang E et al (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Ocnol Biol Phys 79:965–967
McDonald R, Ding K, Brundage M et al (2017) Effect of radiotherapy on painful bone metastases. A secondary analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23. JAMA Oncol 3:953–959
MichaIlski JM, Yan Y, Watkins-Bruner D et al (2013) Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the radiation therapy oncology group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 85:932–938
Pettersson A, Robinson D, Garmo H et al (2018) Age at diagnosis and prostate cancer treatment and prongs: a population based cohort study. Ann Oncol 29:377–385
Roberts CB, Albertsen PC, Shao YH et al (2011) Patterns and correlates of prostate cancer treatment in older men. Am J Med 124:235–243
Vatandoust S, Kichenadasse G, O’Callaghan M et al (2018) Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry. BJU Int 121(Suppl 3):48–54
Widmark A, Klepp O, Soberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SGUO-3); an open randomized phase III trial. Lancet 273:301–308
Wilberg Orrason A, Westerberg M, Garmo H et al (2020) Changes in treatment and mortaility in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int 126:142–151
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this entry
Cite this entry
Stuschke, M., Pöttgen, C., Gauler, T. (2022). Strahlentherapie in der geriatrischen Urologie. In: Michel, M.S., Thüroff, J.W., Janetschek, G., Wirth, M.P. (eds) Die Urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41168-7_231-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-41168-7_231-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-41168-7
Online ISBN: 978-3-642-41168-7
eBook Packages: Springer Referenz Medizin
Publish with us
Chapter history
-
Latest
Strahlentherapie in der geriatrischen Urologie- Published:
- 22 February 2023
DOI: https://doi.org/10.1007/978-3-642-41168-7_231-2
-
Original
Strahlentherapie in der geriatrische Urologie- Published:
- 08 June 2015
DOI: https://doi.org/10.1007/978-3-642-41168-7_231-1